Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Menu
Search
Subscribe
Home
Contact Us
Subscription Services
Promote Your Event
e-Edition
News
Sports
Entertainment
Obituaries
Photos
Videos
e-Edition
Classifieds
Place an Ad
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Invivyd, Inc. - Common Stock
(NQ:
IVVD
)
1.640
+0.040 (+2.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 26, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Invivyd, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19
September 11, 2023
Initial primary endpoint data anticipated in late 2023 or early Q1 2024
From
Invivyd
Via
GlobeNewswire
7 Biotech Stocks to Sell in September Before They Crash & Burn
September 06, 2023
These are just a few of the top biotech stocks to sell today - especially with each of the firms dealing with legitimate issues.
Via
InvestorPlace
Invivyd to Participate in Upcoming Investor Conferences
September 06, 2023
From
Invivyd
Via
GlobeNewswire
What 4 Analyst Ratings Have To Say About Invivyd
June 23, 2023
Via
Benzinga
Invivyd: Q1 Earnings Insights
May 11, 2023
Via
Benzinga
Earnings Preview: Invivyd
May 10, 2023
Via
Benzinga
Invivyd Appoints William Duke as Chief Financial Officer
September 05, 2023
From
Invivyd
Via
GlobeNewswire
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Dentsply, and Invivyd on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
August 16, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
August 10, 2023
Via
Benzinga
Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights
August 10, 2023
From
Invivyd
Via
GlobeNewswire
Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights
August 03, 2023
From
Invivyd
Via
GlobeNewswire
Invivyd Announces Appointment of Sara Cotter to Board Of Directors
July 27, 2023
From
Invivyd
Via
GlobeNewswire
INVIVYD INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Invivyd, Inc. – IVVD, ADGI
July 21, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Earnings Scheduled For August 10, 2023
August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
Via
Benzinga
Invivyd's COVID-19 Antibody Shows Favorable Safety, Tolerability Profile For Immunocompromised People
July 17, 2023
Invivyd Inc (NASDAQ: IVVD) announced additional initial data from its ongoing Phase 1 healthy volunteer clinical trial of its lead investigational monoclonal
Via
Benzinga
Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
July 17, 2023
From
Invivyd
Via
GlobeNewswire
INVIVYD INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Invivyd, Inc. – IVVD, ADGI
July 07, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19
June 26, 2023
From
Invivyd
Via
GlobeNewswire
Invivyd Says Investigational Antibody Shows Potential To Prevent Symptomatic COVID-19
June 22, 2023
Invivyd Inc (NASDAQ: IVVD) announces initial data from its ongoing Phase 1 healthy volunteer clinical trial of VYD222, its investigational monoclonal
Via
Benzinga
Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
June 22, 2023
From
Invivyd
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 01, 2023
Via
Benzinga
Invivyd to Participate at the Jefferies Healthcare Conference
June 01, 2023
From
Invivyd
Via
GlobeNewswire
Why Capri Holdings Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
May 31, 2023
Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) shares jumped 143% to $0.45 after the company announced it received agreement from the FDA on its proposed single confirmatory Phase 3 study of...
Via
Benzinga
INVIVYD ALERT: Bragar Eagel & Squire, P.C. is Investigating Invivyd, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
May 26, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
NASDAQ:IVVD Long Term Investor Alert: Investigation over Potential Wrongdoing at Invivyd, Inc.
May 25, 2023
San Diego, CA -- (SBWIRE) -- 05/25/2023 -- An investigation was announced on behalf of investors in shares of Invivyd, Inc. (NASDAQ:IVVD) over possible breaches of fiduciary duties by certain directors...
Via
SBWire
Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
May 24, 2023
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods.
Via
Benzinga
Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
May 11, 2023
From
Invivyd
Via
GlobeNewswire
Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights
May 04, 2023
From
Invivyd
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
May 01, 2023
Via
Benzinga
Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference
April 25, 2023
From
Invivyd
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.